Get the Stockscreener App
24.79
3.08%
0.74
After Hours:
24.55
-0.24
-0.97%
Promis Neurosciences Inc stock is traded at $24.79, with a volume of 99,376.
It is up +3.08% in the last 24 hours and up +89.24% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$24.05
Open:
$25.03
24h Volume:
99,376
Relative Volume:
0.62
Market Cap:
$53.36M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-124.20
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
+18.84%
1M Performance:
+89.24%
6M Performance:
+130.60%
1Y Performance:
+27.46%
1-Day Range:
$24.00
$27.40
1-Week Range:
$20.27
$27.40
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
24.79 | 51.77M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Promis Neurosciences Inc Stock (PMN) Latest News
Eugene Williams Increases Stake in ProMIS Neurosciences Inc - GuruFocus
Promis Neurosciences (NASDAQ:PMN) Director Eugene Williams Buys 2,000 Shares - MarketBeat
Eugene Williams Acquires 1,000 Shares of Promis Neurosciences (NASDAQ:PMN) Stock - MarketBeat
ProMIS Neurosciences, Inc. (PMN.TO) Competitors - Meyka
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
ProMIS Neurosciences : PMN - 24/7 Wall St.
Ally Bridge entities disclose ProMIS (PMN) shares and warrant terms - Stock Titan
PMN PE Ratio & Valuation, Is PMN Overvalued - Intellectia AI
Can ADMA Biologics Inc deliver consistent EPS growthJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
Insider Buying: Johanne Kaplan Acquires Shares of ProMIS Neurosc - GuruFocus
Insider buy: ProMIS Neurosciences (PMN) CDO acquires 1,629 shares at $15.35 - Stock Titan
Portfolio Shifts: Can ProMIS Neurosciences Inc. continue delivering strong returnsEarnings Beat & Capital Protection Trading Alerts - baoquankhu1.vn
Final Results - ADVFN
What to expect from Gossamer Bio’s late-stage lung disease study - statnews.com
ProMIS Neurosciences CEO touts “watershed year” as PMN310 Alzheimer’s Phase 1b data nears - Defense World
Is ProMIS Neurosciences Inc. stock positioned well for digital economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Promis Neurosciences (NASDAQ:PMN) Cut to “Strong Sell” at Wall Street Zen - Defense World
PMN Should I Buy - Intellectia AI
SPHERA FUNDS MANAGEMENT LTD. Acquires Additional Shares in ProMIS Neurosciences Inc. - GuruFocus
ProMIS Neurosciences: Phase 1b Alzheimer's trial fully enrolled and financed, with pivotal data expected in 2026 - TradingView
Is ProMIS Neurosciences Inc. (23J0) stock a safe buy pre earningsJobs Report & Weekly Breakout Stock Alerts - mfd.ru
Downgrade Watch: Is OPENLANE Inc. on track to beat earningsWeekly Profit Analysis & Verified Technical Signals - baoquankhu1.vn
Guggenheim Remains a Buy on ProMIS Neurosciences (PMN) - The Globe and Mail
Insider Stock Purchases: February 06, 2026 - Quiver Quantitative
ProMIS Neurosciences (PMN) Rating Maintained but Price Target Sl - GuruFocus
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Profit Review: Can ProMIS Neurosciences Inc. continue delivering strong returnsJuly 2025 Trade Ideas & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Short Interest Down 14.8% in January - Defense World
ProMIS Neurosciences, Inc. announced that it expects to receive $75.464029 million in funding from a group of investors - marketscreener.com
ProMIS Neurosciences Announces $75 Million PIPE Financing - The Globe and Mail
ProMIS Neurosciences raises $175 million in PIPE financing By Investing.com - Investing.com South Africa
ProMIS Neurosciences Inc. (PMN) stock: surges 34% after $175M PIPE financing deal - parameter.io
ProMIS Neurosciences Secures $175 Mln In Private Financing - Nasdaq
ProMIS Neurosciences Stock Fluctuates Amid Market Developments - timothysykes.com
ProMIS Neurosciences Signs Multiple Material Agreements - TradingView
ProMIS Neurosciences raises $175 million in PIPE financing - Investing.com
ProMIS Neurosciences stock soars after $175 million private placement By Investing.com - Investing.com South Africa
ProMIS Neurosciences Secures $175 Million in PIPE Financing to Extend Cash Runway and Support Alzheimer’s Disease Clinical Study - Quiver Quantitative
ProMIS Neurosciences stock soars after $175 million private placement - Investing.com
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - The Manila Times
ProMIS lines up up to $175M to extend runway into 2028, fund Alzheimer’s trial - stocktitan.net
RSI Check: What hedge funds are buying Akoya Biosciences IncQuarterly Trade Summary & Free Reliable Trade Execution Plans - baoquankhu1.vn
Aug Breakouts: Whats next for ProMIS Neurosciences Inc stockEarnings Beat & Scalable Portfolio Growth Ideas - baoquankhu1.vn
How cyclical is ProMIS Neurosciences Inc.’s revenue streamMarket Activity Recap & Daily Profit Maximizing Trade Tips - bollywoodhelpline.com
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Quarterly Earnings: Is ProMIS Neurosciences Inc benefiting from innovation trends2025 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Aug Breakouts: Can ProMIS Neurosciences Inc continue delivering strong returnsBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):